Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy
Recruiting
Phase 3
Interventional Study
Chemotherapy Induced Nausea and Vomiting
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 140 (estimated)
- Sponsor
- Mahidol University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* histologically confirmed cancer patients who will be started on first dose of oxaliplatin, irinotecan or carboplatin
* age of \>18 years old
Exclusion Criteria:
* pregnancy or breast feeding
* has emetic episode within 24 hours
* gut obstruction
* uncontrolled brain metastas…
Contacts